# Restore Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/restore-medical-2

- Industry: Healthcare Specialists
- Headquarters: Or Yehuda, Israel
- Website: www.restoremedical.co
- Total disclosed funding: $23M
- Latest round: Series B (Jul 7, 2025)
- Investors on record: 3

## About

Restore Medical Ltd., based in Israel, specializes in developing innovative medical devices for heart failure treatment, focusing on improving patient outcomes with advanced technologies.Founded in 2024 and headquartered in Or Yehuda, Israel, Restore Medical Ltd. is dedicated to creating medical solutions for heart failure. The company's latest financial activity includes a Series B funding round of USD 23 mn raised on July 7, 2025, co-led by Pitango HealthTech and the European Innovation Council, with participation from Peregrine Ventures. No notable pivots in business strategy or information regarding subsidiaries have been mentioned.Restore Medical's principal product is the ContraBand™, a pioneering transcatheter Pulmonary Artery Banding (PAB) system designed specifically for patients suffering from heart failure with reduced ejection fraction (HFrEF). The device targets the complications associated with left ventricular (LV) failure, providing support via a catheter-delivered implant that enhances the LV's ejection fraction. This innovative therapy offers a reversible and less invasive alternative to existing treatments, primarily targeting hospitals, cardiologists, and healthcare providers specializing in heart failure management, particularly in the United States and select European markets.The revenue model for Restore Medical revolves around sales of its flagship product, ContraBand™, targeting healthcare institutions such as hospitals and specialized clinics. The company engages in direct sales, with healthcare providers integrating ContraBand™ into their treatment protocols for patients with LV failure. The sales structure involves procurement agreements wherein hospitals order devices based on anticipated patient needs, ensuring consistent revenue generation aligned with industry standards for advanced cardiac therapies.Following the Series B funding round of USD 23 mn completed in July 2025, Restore Medical plans to utilize these funds to accelerate feasibility testing and enhance the remodeling, performance, and functional capacity of its products. The company aims to expand its market presence, particularly targeting new regions in the United States and Europe where heart failure is prevalent, with a focus on bringing new products to market as part of its growth strategy.

## Funding rounds

- Series B, Jul 7, 2025, $23M — Pitango, Peregrine Ventures, European Innovation Council
- Series A, Mar 27, 2023 — Peregrine Ventures
- Series A, Mar 1, 2022 — Peregrine Ventures

## Investors

- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Series A, Series B
- Pitango (https://capitalatlas.ai/funds/pitango) — Series B
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series B